150 related articles for article (PubMed ID: 19581734)
21. What options are available for refractory pancreatic cancer?
Choi M; Kim R; Saif MW
JOP; 2012 Mar; 13(2):163-5. PubMed ID: 22406591
[TBL] [Abstract][Full Text] [Related]
22. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
[TBL] [Abstract][Full Text] [Related]
23. Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Richter J; Saif MW
JOP; 2010 Mar; 11(2):144-7. PubMed ID: 20208323
[TBL] [Abstract][Full Text] [Related]
24. Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer.
Li L; Zhang JW; Jenkins G; Xie F; Carlson EE; Fridley BL; Bamlet WR; Petersen GM; McWilliams RR; Wang L
Pharmacogenet Genomics; 2016 Dec; 26(12):527-537. PubMed ID: 27749787
[TBL] [Abstract][Full Text] [Related]
25. Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Ciccolini J; Mercier C; Dahan L; André N
Nat Rev Clin Oncol; 2011 Feb; 8(7):439-44. PubMed ID: 21304503
[TBL] [Abstract][Full Text] [Related]
26. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Innocenti F; Owzar K; Cox NL; Evans P; Kubo M; Zembutsu H; Jiang C; Hollis D; Mushiroda T; Li L; Friedman P; Wang L; Glubb D; Hurwitz H; Giacomini KM; McLeod HL; Goldberg RM; Schilsky RL; Kindler HL; Nakamura Y; Ratain MJ
Clin Cancer Res; 2012 Jan; 18(2):577-84. PubMed ID: 22142827
[TBL] [Abstract][Full Text] [Related]
27. New developments in the treatment of locally advanced pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Triano LR; Chang BW; Saif MW
JOP; 2009 Jul; 10(4):366-72. PubMed ID: 19581736
[TBL] [Abstract][Full Text] [Related]
28. Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.
Liang D; Shi S; Liang C; Meng Q; Zhang B; Ni Q; Xu J; Yu X
Surgery; 2018 May; 163(5):1080-1089. PubMed ID: 29352574
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Saif MW; Kang SP; Ledbetter L; Steg A; Diasio R; Johnson M
JOP; 2007 Nov; 8(6):799-805. PubMed ID: 17993734
[TBL] [Abstract][Full Text] [Related]
30. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine in the treatment of metastatic pancreatic cancer.
Hilbig A; Oettle H
Expert Rev Anticancer Ther; 2008 Apr; 8(4):511-23. PubMed ID: 18402518
[TBL] [Abstract][Full Text] [Related]
32. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
Williams TK; Costantino CL; Bildzukewicz NA; Richards NG; Rittenhouse DW; Einstein L; Cozzitorto JA; Keen JC; Dasgupta A; Gorospe M; Gonye GE; Yeo CJ; Witkiewicz AK; Brody JR
PLoS One; 2010 Nov; 5(11):e15455. PubMed ID: 21152064
[TBL] [Abstract][Full Text] [Related]
33. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
Xie H; Jiang W; Xiao SY; Liu X
J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
Ohuchida K; Mizumoto K; Kayashima T; Fujita H; Moriyama T; Ohtsuka T; Ueda J; Nagai E; Hashizume M; Tanaka M
Ann Surg Oncol; 2011 Aug; 18(8):2381-7. PubMed ID: 21347785
[TBL] [Abstract][Full Text] [Related]
35. Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.
Matsubara J; Ono M; Honda K; Negishi A; Ueno H; Okusaka T; Furuse J; Furuta K; Sugiyama E; Saito Y; Kaniwa N; Sawada J; Shoji A; Sakuma T; Chiba T; Saijo N; Hirohashi S; Yamada T
Mol Cell Proteomics; 2010 Apr; 9(4):695-704. PubMed ID: 20061307
[TBL] [Abstract][Full Text] [Related]
36. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
Si S; Liao Q; Zhao YP; Hu Y; Zhang Q; You LL
Chin Med J (Engl); 2011 Feb; 124(3):419-22. PubMed ID: 21362344
[TBL] [Abstract][Full Text] [Related]
37. Personalized medicine for pancreatic cancer: a step in the right direction.
Ko AH; Tempero MA
Gastroenterology; 2009 Jan; 136(1):43-5. PubMed ID: 19041649
[No Abstract] [Full Text] [Related]
38. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.
Urey C; Andersson B; Ansari D; Sasor A; Said-Hilmersson K; Nilsson J; Andersson R
Scand J Gastroenterol; 2017 May; 52(5):595-600. PubMed ID: 28270046
[TBL] [Abstract][Full Text] [Related]
39. [Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Gligorov J; André T; Epaud C; Culine S
Bull Cancer; 2002 Aug; 89 Spec No():S134-44. PubMed ID: 12449045
[TBL] [Abstract][Full Text] [Related]
40. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Innocenti F; Owzar K; Jiang C; Etheridge AS; Gordân R; Sibley AB; Mulkey F; Niedzwiecki D; Glubb D; Neel N; Talamonti MS; Bentrem DJ; Seiser E; Yeh JJ; Van Loon K; McLeod H; Ratain MJ; Kindler HL; Venook AP; Nakamura Y; Kubo M; Petersen GM; Bamlet WR; McWilliams RR
PLoS One; 2018; 13(8):e0202272. PubMed ID: 30107003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
